STVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Stevanato Group SpA (STVN) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the stock has shown some positive pre-market movement and has a solid business foundation, the lack of strong proprietary trading signals, mixed financial performance, and recent downward revisions in analyst price targets suggest holding off on immediate investment.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 78.409, and moving averages are converging, which does not provide a clear directional signal. The stock is trading near resistance levels (R1: 14.929, R2: 15.363) in pre-market, which could limit further upside in the short term.
The company has shown revenue growth of 4.81% YoY in Q4 2025, and gross margin increased by 3.45% YoY, indicating operational efficiency. Analysts highlight robust demand across biologics and a structural shift toward premium formats, which could support long-term growth.
Net income and EPS have declined YoY, reflecting profitability challenges. Analysts have broadly lowered price targets, citing near-term engineering weakness and order softness. The stock has a 60% chance to decline in the next day and month, based on trend analysis. Additionally, there is no recent news or congress trading data to suggest a significant positive catalyst.
In Q4 2025, revenue grew by 4.81% YoY to $346.48M, but net income dropped by 1.57% YoY to $47.55M, and EPS decreased by 5.56% YoY to $0.17. While gross margin improved to 31.81%, the decline in profitability metrics raises concerns about the company's ability to sustain earnings growth.
Analysts have recently lowered price targets across the board, with Morgan Stanley reducing its target to $19, Citi to $26, KeyBanc to $32, BofA to $28, and Jefferies to $17.50. While some analysts maintain Buy or Overweight ratings, the consistent downward revisions reflect cautious sentiment due to near-term challenges in the company's core business.
